Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Jana L. Gevertz"'
Autor:
Irina Kareva, Jana L. Gevertz
Publikováno v:
npj Systems Biology and Applications, Vol 10, Iss 1, Pp 1-13 (2024)
Abstract Despite the revolutionary impact of immune checkpoint inhibition on cancer therapy, the lack of response in a subset of patients, as well as the emergence of resistance, remain significant challenges. Here we explore the theoretical conseque
Externí odkaz:
https://doaj.org/article/686dda4cb20e46a582e890d5d78c6b22
Autor:
Jana L. Gevertz, Irina Kareva
Publikováno v:
npj Systems Biology and Applications, Vol 10, Iss 1, Pp 1-14 (2024)
Abstract Mathematical models are increasingly being developed and calibrated in tandem with data collection, empowering scientists to intervene in real time based on quantitative model predictions. Well-designed experiments can help augment the predi
Externí odkaz:
https://doaj.org/article/a143c81b81f348e388963f995751870f
Autor:
Jana L. Gevertz, Irina Kareva
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 11, Pp 1698-1713 (2023)
Abstract Despite the growing appreciation that the future of cancer treatment lies in combination therapies, finding the right drugs to combine and the optimal way to combine them remains a nontrivial task. Herein, we introduce the Multi‐Objective
Externí odkaz:
https://doaj.org/article/013cd791e6a74884b9b8c1622db344d7
Autor:
Santiago D. Cárdenas, Constance J. Reznik, Ruchira Ranaweera, Feifei Song, Christine H. Chung, Elana J. Fertig, Jana L. Gevertz
Publikováno v:
npj Systems Biology and Applications, Vol 8, Iss 1, Pp 1-11 (2022)
Abstract The promise of precision medicine has been limited by the pervasive resistance to many targeted therapies for cancer. Inferring the timing (i.e., pre-existing or acquired) and mechanism (i.e., drug-induced) of such resistance is crucial for
Externí odkaz:
https://doaj.org/article/1199c17957c74b108d4b5b9e167bcb2a
Publikováno v:
Frontiers in Systems Biology, Vol 3 (2023)
Mathematical modeling has made significant contributions to drug design, development, and optimization. Virtual clinical trials that integrate mathematical models to explore patient heterogeneity and its impact on a variety of therapeutic questions h
Externí odkaz:
https://doaj.org/article/f50af397fc1a4caca575892192aa338e
Autor:
Joanna R. Wares, Jing Dong, Jana L. Gevertz, Ami Radunskaya, Kendra Vine, Doug Wiebe, Sara Solomon
Publikováno v:
Harm Reduction Journal, Vol 18, Iss 1, Pp 1-11 (2021)
Abstract Background Fatal overdoses from opioid use and substance disorders are increasing at an alarming rate. One proposed harm reduction strategy for reducing overdose fatalities is to place overdose prevention sites—commonly known as safe injec
Externí odkaz:
https://doaj.org/article/5744f5b526c946259fa82e12535c6b16
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
An outstanding challenge in the clinical care of cancer is moving from a one-size-fits-all approach that relies on population-level statistics towards personalized therapeutic design. Mathematical modeling is a powerful tool in treatment personalizat
Externí odkaz:
https://doaj.org/article/f2eea593943d4abfb90126bedd6e0d76
Autor:
Joanna R. Wares, Jing Dong, Jana L. Gevertz, Ami Radunskaya, Kendra Viner, Doug Wiebe, Sara Solomon
Publikováno v:
Harm Reduction Journal, Vol 18, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/9b4c1a4bf4bc45dd925c29222300be0b
Autor:
Jana L. Gevertz, Salvatore Torquato
Publikováno v:
PLoS Computational Biology, Vol 5, Iss 1 (2009)
Externí odkaz:
https://doaj.org/article/5809f6b049c54ab8a7f886eee4cc5a00
Publikováno v:
Frontiers in Oncology. 12
An outstanding challenge in the clinical care of cancer is moving from a one-size-fits-all approach that relies on population-level statistics towards personalized therapeutic design. Mathematical modeling is a powerful tool in treatment personalizat